Bone Biologics Co. (NASDAQ:BBLG) Short Interest Up 9.8% in January

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 55,100 shares, an increase of 9.8% from the December 31st total of 50,200 shares. Based on an average daily volume of 224,100 shares, the short-interest ratio is presently 0.2 days. Currently, 10.3% of the company’s stock are short sold.

Bone Biologics Stock Performance

Bone Biologics stock opened at $1.27 on Tuesday. The firm has a 50-day moving average of $1.07 and a 200-day moving average of $1.42. Bone Biologics has a one year low of $0.80 and a one year high of $4.74.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.